Mulligan N, et al. - Researchers aimed at evaluating dolutegravir pharmacokinetics during pregnancy compared with postpartum and in infant washout samples after delivery. They noted lower dolutegravir exposure in pregnancy compared with postpartum in the same women on once-daily dosing. Compared to nonpregnant adults, pregnant women exhibited similar median AUC_0–24 but lower trough concentrations. In pregnancy, trough concentrations were well above dolutegravir EC₉₀ (0.064μg/ml). Dolutegravir readily crossed the placenta. Prolonged infant elimination was evident, with half-life over twice that of historical adult controls.